Proteomic analysis reveals a potential anticancer mechanism for a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin inclusion complex towards colorectal cancer cells through modulation of ribosome biogenesis
{"title":"Proteomic analysis reveals a potential anticancer mechanism for a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin inclusion complex towards colorectal cancer cells through modulation of ribosome biogenesis","authors":"Atthapan Morchang , Keerakarn Somsuan , Artitaya Rongjumnong , Churat Weeraphan , Sasivimon Pramual , Theetat Ruangjaroon , Daranee Chokchaichamnankit , Wuttichai Jaidee , Phateep Hankittichai , Chanatip Pramvichai , Rawiwan Charoensup , Arunothai Wanta , Chantragan Srisomsap , Jisnuson Svasti , Siripat Aluksanasuwan","doi":"10.1016/j.carpta.2025.100775","DOIUrl":null,"url":null,"abstract":"<div><div>Colorectal cancer (CRC) is a major global health issue due to its aggressiveness and high mortality rates. While curcumin, the bioactive compound from turmeric (<em>Curcuma longa</em> L.), exhibits anticancer properties, its low water solubility limits therapeutic potential. The present study developed a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin (CUR-A-Poly-β-CD) inclusion complex to enhance solubility and evaluated its anticancer potential in CRC cell lines. The complex exhibited a zeta potential of -22.9 ± 1.1 mV, a particle size of 496.8 ± 1.9 nm, a solubility of 13.6 mg/L, and a pH of 4.5. CUR-A-Poly-β-CD was non-toxic to normal colon cells (CCD-841 CoN) but significantly reduced the viability of CRC cell lines HT-29, SW-48, and SW-480, with SW-480 cells being the most responsive. CUR-A-Poly-β-CD induced apoptosis and inhibited proliferation, clonogenicity, and migration of SW-480 cells. Proteomic analysis identified 105 altered proteins in SW-480 cells treated with CUR-A-Poly-β-CD, primarily involved in cell growth and ribosome biogenesis pathways. Western blot analysis confirmed increased levels of ribosomal proteins RPL13a and RPS3. In conclusion, the CUR-A-Poly-β-CD inclusion complex demonstrates anticancer effects against CRC by modulating ribosome biogenesis. These findings suggest its potential as a therapeutic approach to improve the effectiveness of CRC treatments.</div></div>","PeriodicalId":100213,"journal":{"name":"Carbohydrate Polymer Technologies and Applications","volume":"10 ","pages":"Article 100775"},"PeriodicalIF":6.2000,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Carbohydrate Polymer Technologies and Applications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666893925001148","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
引用次数: 0
Abstract
Colorectal cancer (CRC) is a major global health issue due to its aggressiveness and high mortality rates. While curcumin, the bioactive compound from turmeric (Curcuma longa L.), exhibits anticancer properties, its low water solubility limits therapeutic potential. The present study developed a novel effervescent curcumin-ascorbic acid-polysaccharide-β-cyclodextrin (CUR-A-Poly-β-CD) inclusion complex to enhance solubility and evaluated its anticancer potential in CRC cell lines. The complex exhibited a zeta potential of -22.9 ± 1.1 mV, a particle size of 496.8 ± 1.9 nm, a solubility of 13.6 mg/L, and a pH of 4.5. CUR-A-Poly-β-CD was non-toxic to normal colon cells (CCD-841 CoN) but significantly reduced the viability of CRC cell lines HT-29, SW-48, and SW-480, with SW-480 cells being the most responsive. CUR-A-Poly-β-CD induced apoptosis and inhibited proliferation, clonogenicity, and migration of SW-480 cells. Proteomic analysis identified 105 altered proteins in SW-480 cells treated with CUR-A-Poly-β-CD, primarily involved in cell growth and ribosome biogenesis pathways. Western blot analysis confirmed increased levels of ribosomal proteins RPL13a and RPS3. In conclusion, the CUR-A-Poly-β-CD inclusion complex demonstrates anticancer effects against CRC by modulating ribosome biogenesis. These findings suggest its potential as a therapeutic approach to improve the effectiveness of CRC treatments.